AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PF-06412528 IN CHILDREN 7-17 YEARS FOR THE TREATMENT OF MODERATE-TO-SEVERE PAIN
Phase of Trial: Phase IV
Latest Information Update: 30 Aug 2019
Price : $35 *
At a glance
- Drugs Morphine/naltrexone (Primary)
- Indications Pain
- Focus Pharmacokinetics
- Sponsors Pfizer
- 25 Jul 2019 Status changed from recruiting to completed.
- 01 Feb 2019 Planned End Date changed from 1 Dec 2019 to 21 Dec 2019.
- 01 Feb 2019 Planned primary completion date changed from 1 Dec 2019 to 21 Dec 2019.